miRNAs as prognostic and therapeutic tools in epithelial ovarian cancer

Biomarkers in Medicine

Volumn 9, Issue 3, 2015, Pages 241-257

  Nagaraj, Anil Belur ^a   Joseph, Peronne ^a   DiFeo, Analisa ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

biomarkers; chemotherapy resistance; epithelial ovarian cancer; miRNA expression profiling; miRNAs; MRX34; OncomiRs; pharmaco miR; tumor heterogeneity; tumor suppressor miRs

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; ERLOTINIB; MICRORNA; MRX 34; PLATINUM COMPLEX; UNCLASSIFIED DRUG; BIOMIMETIC MATERIAL; TUMOR MARKER;

CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL MIGRATION; EARLY DIAGNOSIS; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC HETEROGENEITY; HUMAN; IMMUNOMODULATION; IMMUNOPHENOTYPING; OVARY CARCINOMA; OVERALL SURVIVAL; PATHOGENESIS; PHARMACOGENOMICS; PHENOTYPE; PREDICTION; PROTEIN PROCESSING; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW; TUMOR INVASION; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE; ANIMAL; GENETICS; METABOLISM; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS;

ANIMALS; BIOMIMETIC MATERIALS; HUMANS; MICRORNAS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84923916219     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.14.108     Document Type: Review

References (123)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA-Cancer J. Clin. 64(1), 9-29 (2014).
2. Cooke SL, Brenton JD. Evolution of platinum resistance in high-grade serous ovarian cancer. Lancet Oncol. 12(12), 1169-1174 (2011).
3. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat. Rev. Genet. 5(7), 522-531 (2004).
4. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116(2), 281-297 (2004).
5. Kim VN. MicroRNA biogenesis: coordinated cropping and dicing. Nat. Rev. Mol. Cell Biol. 6(5), 376-385 (2005).
6. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat. Rev. Cancer 6(11), 857-866 (2006).
7. Iorio MV, Visone R, Di Leva G et al. MicroRNA signatures in human ovarian cancer. Cancer Res. 67(18), 8699-8707 (2007).
8. Mezzanzanica D, Bagnoli M, De Cecco L, Valeri B, Canevari S. Role of microRNAs in ovarian cancer pathogenesis and potential clinical implications. Int. J. Biochem. Cell B. 42(8), 1262-1272 (2010).
9. Pencheva N, Tavazoie SF. Control of metastatic progression by microRNA regulatory networks. Nat. Cell Biol. 15(6), 546-554 (2013).
10. Sun X, Jiao X, Pestell TG et al. MicroRNAs and cancer stem cells: the sword and the shield. Oncogene 33(42), 4967-4977 (2014).
11. Garofalo M, Croce CM. MicroRNAs as therapeutic targets in chemoresistance. Drug Resist. Updat. 16(3-5), 47-59 (2013).
12. Van Jaarsveld MT, Helleman J, Berns EM, Wiemer EA. MicroRNAs in ovarian cancer biology and therapy resistance. Int. J. Biochem. Cell B. 42(8), 1282-1290 (2010).
13. Frederick PJ, Green HN, Huang JS et al. Chemoresistance in ovarian cancer linked to expression of microRNAs. Biotech Histochem. 88(7), 403-409 (2013).
14. Shen DW, Pouliot LM, Hall MD, Gottesman MM. Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol. Rev. 64(3), 706-721 (2012).
15. Cooke SL, Ng CK, Melnyk N et al. Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma. Oncogene 29(35), 4905-4913 (2010).
16. Latifi A, Abubaker K, Castrechini N et al. Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile. J Cell. Biochem. 112(10), 2850-2864 (2011).
17. Abubaker K, Latifi A, Luwor R et al. Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden. Mol. Cancer 12, 24 (2013).
18. Weigelt B, Reis-Filho JS, Swanton C. Genomic analyses to select patients for adjuvant chemotherapy: trials and tribulations. Ann. Oncol. 23(Suppl. 10), x211-x218 (2012).
19. Banerjee S, Gore M. The future of targeted therapies in ovarian cancer. Oncologist 14(7), 706-716 (2009).
20. Gupta D, Lis CG. Role of CA125 in predicting ovarian cancer survival: a review of the epidemiological literature. J. Ovarian Res. 2, 13 (2009).
21. Felder M, Kapur A, Gonzalez-Bosquet J et al. MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress. Mol. Cancer 13, 129 (2014).
22. Lu J, Getz G, Miska EA et al. MicroRNA expression profiles classify human cancers. Nature 435(7043), 834-838 (2005).
23. Xi Y, Nakajima G, Gavin E et al. Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA 13(10), 1668-1674 (2007).
24. Mitchell PS, Parkin RK, Kroh EM et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl Acad. Sci. USA 105(30), 10513-10518 (2008).
25. Llaurado M, Majem B, Altadill T et al. MicroRNAs as prognostic markers in ovarian cancer. Mol. Cell. Endocrinol. 390(1-2), 73-84 (2014).
26. Pritchard CC, Cheng HH, Tewari M. MicroRNA profiling: approaches and considerations. Nat. Rev. Genet. 13(5), 358-369 (2012).
27. Baker M. MicroRNA profiling: separating signal from noise. Nat. Methods 7(9), 687-692 (2010).
28. Donadeu FX, Schauer SN, Sontakke SD. Involvement of miRNAs in ovarian follicular and luteal development. J. Endocrinol. 215(3), 323-334 (2012).
29. Liu Z, Liu J, Segura MF et al. MiR-182 overexpression in tumourigenesis of high-grade serous ovarian carcinoma. J. Pathol. 228(2), 204-215 (2012).
30. Perets R, Wyant GA, Muto KW et al. Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell 24(6), 751-765 (2013).
31. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474(7353), 609-615 (2011).
32. Krell J, Frampton AE, Colombo T et al. The p53 miRNA interactome and its potential role in the cancer clinic. Epigenomics 5(4), 417-428 (2013).
33. Lee CH, Subramanian S, Beck AH et al. MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutationcarrying high-grade serous carcinomas of ovary. PLoS ONE 4(10), e7314 (2009).
34. Creighton CJ, Fountain MD, Yu Z et al. Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers. Cancer Res. 70(5), 1906-1915 (2010).
35. Hu X, Macdonald DM, Huettner PC et al. A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecol. Oncol. 114(3), 457-464 (2009).
36. Nam EJ, Yoon H, Kim SW et al. MicroRNA expression profiles in serous ovarian carcinoma. Clin. Cancer Res. 14(9), 2690-2695 (2008).
37. Kim TH, Kim YK, Kwon Y et al. Deregulation of miR-519a, 153, and 485-5p and its clinicopathological relevance in ovarian epithelial tumours. Histopathol. 57(5), 734-743 (2010).
38. Yang D, Sun Y, Hu L et al. Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell 23(2), 186-199 (2013).
39. Eitan R, Kushnir M, Lithwick-Yanai G et al. Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients. Gynecol. Oncol. 114(2), 253-259 (2009).
40. Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G, Ferlini C. Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol. Oncol. 111(3), 478-486 (2008).
41. Yang N, Kaur S, Volinia S et al. MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res. 68(24), 10307-10314 (2008).
42. Bagnoli M, De Cecco L, Granata A et al. Identification of a chrXq27.3 microRNA cluster associated with early relapse in advanced stage ovarian cancer patients. Oncotarget 2(12), 1265-1278 (2011).
43. Parikh A, Lee C, Peronne J et al. microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition. Nat. Comms. 5, 2977 (2014).
44. Schwarzenbach H, Nishida N, Calin GA, Pantel K. Clinical relevance of circulating cell-free microRNAs in cancer. Nat. Rev. Clin. Oncol. 11(3), 145-156 (2014).
45. Maclellan SA, Macaulay C, Lam S, Garnis C. Pre-profiling factors influencing serum microRNA levels. BMC Clin. Pathol. 14, 27 (2014).
46. Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM, Cohn DE. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol. Oncol. 112(1), 55-59 (2009).
47. Kan CW, Hahn MA, Gard GB et al. Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer. BMC Cancer 12, 627 (2012).
48. Hong F, Li Y, Xu Y, Zhu L. Prognostic significance of serum microRNA-221 expression in human epithelial ovarian cancer. J. Int. Med. Res. 41(1), 64-71 (2013).
49. Xu YZ, Xi QH, Ge WL, Zhang XQ. Identification of serum microRNA-21 as a biomarker for early detection and prognosis in human epithelial ovarian cancer. Asian Pac. J. Cancer Prev. 14(2), 1057-1060 (2013).
50. Guo F, Tian J, Lin Y, Jin Y, Wang L, Cui M. Serum microRNA-92 expression in patients with ovarian epithelial carcinoma. J. Int. Med. Res. 41(5), 1456-1461 (2013).
51. Zheng H, Zhang L, Zhao Y et al. Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer. PLoS ONE 8(11), e77853 (2013).
52. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol. Oncol. 110(1), 13-21 (2008).
53. Moret I, Sanchez-Izquierdo D, Iborra M et al. Assessing an improved protocol for plasma microRNA extraction. PLoS ONE 8(12), e82753 (2013).
54. Chevillet JR, Kang Q, Ruf IK et al. Quantitative and stoichiometric analysis of the microRNA content of exosomes. Proc. Natl Acad. Sci. USA 111(41), 14888-14893 (2014).
55. Li Z, Rana TM. Therapeutic targeting of microRNAs: current status and future challenges. Nat. Rev. Drug Discov. 13(8), 622-638 (2014).
56. Nana-Sinkam SP, Croce CM. MicroRNA dysregulation in cancer: opportunities for the development of microRNA-based drugs. IDrugs 13(12), 843-846 (2010).
57. Corney DC, Hwang CI, Matoso A et al. Frequent downregulation of miR-34 family in human ovarian cancers. Clin. Cancer Res. 16(4), 1119-1128 (2010).
58. Rukov JL, Wilentzik R, Jaffe I, Vinther J, Shomron N. Pharmaco-miR: linking microRNAs and drug effects. Brief. Bioinf. 15(4), 648-659 (2014).
59. Yin D, Ogawa S, Kawamata N et al. miR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme. Oncogene 32(9), 1155-1163 (2013).
60. Zhao J, Kelnar K, Bader AG. In-depth analysis shows synergy between erlotinib and miR-34a. PLoS ONE 9(2), e89105 (2014).
61. Siwak DR, Carey M, Hennessy BT et al. Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges. J. Oncol. 2010, 568938 (2010).
62. Nishimura M, Jung EJ, Shah MY et al. Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment. Cancer Discov. 3(11), 1302-1315 (2013).
63. Galluzzi L, Senovilla L, Vitale I et al. Molecular mechanisms of cisplatin resistance. Oncogene 31(15), 1869-1883 (2012).
64. Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ. 17(2), 193-199 (2010).
65. Taylor MA, Sossey-Alaoui K, Thompson CL, Danielpour D, Schiemann WP. TGF-beta upregulates miR-181a expression to promote breast cancer metastasis. J. Clin. Invest. 123(1), 150-163 (2013).
66. Wang J, Zhou JY, Wu GS. Bim protein degradation contributes to cisplatin resistance. J. Biol. Chem. 286(25), 22384-22392 (2011).
67. Steg AD, Bevis KS, Katre AA et al. Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin. Cancer Res. 18(3), 869-881 (2012).
68. Deng S, Yang X, Lassus H et al. Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS ONE 5(4), e10277 (2010).
69. Silva IA, Bai S, Mclean K et al. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res. 71(11), 3991-4001 (2011).
70. Wang Y, Kim S, Kim IM. Regulation of metastasis by microRNAs in ovarian cancer. Front. Oncol. 4, 143 (2014).
71. Xu CX, Xu M, Tan L et al. MicroRNA miR-214 regulates ovarian cancer cell stemness by targeting p53/Nanog. J. Biol. Chem. 287(42), 34970-34978 (2012).
72. Park YT, Jeong JY, Lee MJ et al. MicroRNAs overexpressed in ovarian ALDH1-positive cells are associated with chemoresistance. J. Ovarian Res. 6(1), 18 (2013).
73. Sui H, Cai GX, Pan SF et al. miR-200c attenuates P-gp mediated MDR and metastasis by targeting JNK2/c-Jun signaling pathway in colorectal cancer. Mol. Cancer Ther.13(12), 3137-3151 (2014).
74. Lengyel E. Ovarian cancer development and metastasis. Am. J. Pathol. 177(3), 1053-1064 (2010).
75. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat. Rev. Mol. Cell Biol. 15(3), 178-196 (2014).
76. Zhang J, Ma L. MicroRNA control of epithelial-mesenchymal transition and metastasis. Cancer Mestat. Rev 31(3-4), 653-662 (2012).
77. Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 22(7), 894-907 (2008).
78. + ovarian cancer stem cells by regulating epithelial-mesenchymal transition. J. Ovarian Res. 6(1), 50 (2013).
79. Cowden Dahl KD, Dahl R, Kruichak JN, Hudson LG. The epidermal growth factor receptor responsive miR-125a represses mesenchymal morphology in ovarian cancer cells. Neoplasia 11(11), 1208-1215 (2009).
80. Yeh YM, Chuang CM, Chao KC, Wang LH. MicroRNA-138 suppresses ovarian cancer cell invasion and metastasis by targeting SOX4 and HIF-1alpha. Int. J. Cancer 133(4), 867-878 (2013).
81. Junttila MR, De Sauvage FJ. Influence of tumour microenvironment heterogeneity on therapeutic response. Nature 501(7467), 346-354 (2013).
82. Musrap N, Diamandis EP. Revisiting the complexity of the ovarian cancer microenvironment - clinical implications for treatment strategies. Mol. Cancer Res. 10(10), 1254-1264 (2012).
83. Suzuki HI, Katsura A, Matsuyama H, Miyazono K. MicroRNA regulons in tumor microenvironment. Oncogene doi:10.1038/onc.2014.254 (2014) (Epub ahead of print).
84. Mitra AK, Zillhardt M, Hua Y et al. MicroRNAs reprogram normal fibroblasts into cancer-associated fibroblasts in ovarian cancer. Cancer Discov. 2(12), 1100-1108 (2012).
85. Ling H, Fabbri M, Calin GA. MicroRNAs and other noncoding RNAs as targets for anticancer drug development. Nat. Rev. Drug Discov. 12(11), 847-865 (2013).
86. Armstrong DK, Bundy B, Wenzel L et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 354(1), 34-43 (2006).
87. Zhang Y, Kenny HA, Swindell EP et al. Urokinase plasminogen activator system-targeted delivery of nanobins as a novel ovarian cancer therapy. Mol. Cancer Ther. 12(12), 2628-2639 (2013).
88. Bedard PL, Hansen AR, Ratain MJ, Siu LL. Tumour heterogeneity in the clinic. Nature 501(7467), 355-364 (2013).
89. Bashashati A, Ha G, Tone A et al. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. J. Pathol. 231(1), 21-34 (2013).
90. Raychaudhuri M, Schuster T, Buchner T et al. Intratumoral heterogeneity of microRNA expression in breast cancer. J. Mol. Diagn. 14(4), 376-384 (2012).
91. Onstenk W, Gratama JW, Foekens JA, Sleijfer S. Towards a personalized breast cancer treatment approach guided by circulating tumor cell (CTC) characteristics. Cancer Treat. Rev. 39(7), 691-700 (2013).
92. Liu JF, Kindelberger D, Doyle C, Lowe A, Barry WT, Matulonis UA. Predictive value of circulating tumor cells (CTCs) in newly-diagnosed and recurrent ovarian cancer patients. Gynecol. Oncol. 131(2), 352-356 (2013).
93. Vasudevan S, Tong Y, Steitz JA. Switching from repression to activation: microRNAs can up-regulate translation. Science 318(5858), 1931-1934 (2007).
94. Liu M, Roth A, Yu M et al. The IGF2 intronic miR-483 selectively enhances transcription from IGF2 fetal promoters and enhances tumorigenesis. Genes Dev. 27(23), 2543-2548 (2013).
95. Cai J, Yang C, Yang Q et al. Deregulation of let-7e in epithelial ovarian cancer promotes the development of resistance to cisplatin. Oncogenesis 2, e75 (2013).
96. Yu PN, Yan MD, Lai HC et al. Downregulation of miR-29 contributes to cisplatin resistance of ovarian cancer cells. Int. J. Cancer 134(3), 542-551 (2014).
97. Xiang Y, Ma N, Wang D et al. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine. Oncogene 33(3), 378-386 (2014).
98. Liu MX, Siu MK, Liu SS, Yam JW, Ngan HY, Chan DW. Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch1 signaling in ovarian cancer. Oncotarget 5(4), 944-958 (2014).
99. Zhou Y, Chen Q, Qin R, Zhang K, Li H. MicroRNA-449a reduces cell survival and enhances cisplatin-induced cytotoxicity via downregulation of NOTCH1 in ovarian cancer cells. Tumour Biol. 35(12), 12369-12378 (2014).
100. Vecchione A, Belletti B, Lovat F et al. A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis. Proc. Natl Acad. Sci. USA 110(24), 9845-9850 (2013).
101. Sun C, Li N, Yang Z et al. miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition. J. Natl Cancer Inst. 105(22), 1750-1758 (2013).
102. Chan JK, Blansit K, Kiet T et al. The inhibition of miR-21 promotes apoptosis and chemosensitivity in ovarian cancer. Gynecol. Oncol. 132(3), 739-744 (2014).
103. Liu SG, Fang Y, Shen HL, Xu WL, Li H. Berberine sensitizes ovarian cancer cells to cisplatin through miR-21/PDCD4 axis. Acta Bioch. Bioph. Sin. 45(9), 756-762 (2013).
104. Jia W, Eneh JO, Ratnaparkhe S, Altman MK, Murph MM. MicroRNA-30c-2∗ expressed in ovarian cancer cells suppresses growth factor-induced cellular proliferation and downregulates the oncogene BCL9. Mol. Cancer Res. 9(12), 1732-1745 (2011).
105. Lacroix B, Gamazon ER, Lenkala D et al. Integrative analyses of genetic variation, epigenetic regulation, and the transcriptome to elucidate the biology of platinum sensitivity. BMC Genomics 15, 292 (2014).
106. Fu X, Tian J, Zhang L, Chen Y, Hao Q. Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells. FEBS Lett. 586(9), 1279-1286 (2012).
107. Huang JW, Wang YM, Dhillon KK et al. Systematic screen identifies miRNAs that target RAD51 and RAD51D to enhance chemosensitivity. Mol. Cancer Res. 11(12), 1564-1573 (2013).
108. Rao YM, Shi HR, Ji M, Chen CH. MiR-106a targets Mcl-1 to suppress cisplatin resistance of ovarian cancer A2780 cells. J. Huazhong Univ. Sci. Technol. Med. Sci. 33(4), 567-572 (2013).
109. Kong F, Sun C, Wang Z et al. miR-125b confers resistance of ovarian cancer cells to cisplatin by targeting pro-apoptotic Bcl-2 antagonist killer 1. J. Huazhong Univ. Sci. Technol. Med. Sci. 31(4), 543-549 (2011).
110. Li NW, Wang HJ, Yang LY, Jia XB, Chen C, Wang X. [Regulatory effects and associated mechanisms of miR-130a molecules on cisplatin resistance in ovarian cancer A2780 cell lines]. Sichuan Da Xue Xue Bao Yi Xue Ban 44(6), 865-870 (2013).
111. Zhang X, Huang L, Zhao Y, Tan W. Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly. Acta Biochim. Biophys. Sin. (Shanghai) 45(12), 995-1001 (2013).
112. Yang C, Cai J, Wang Q et al. Epigenetic silencing of miR-130b in ovarian cancer promotes the development of multidrug resistance by targeting colony-stimulating factor 1. Gynecol. Oncol. 124(2), 325-334 (2012).
113. Van Jaarsveld MT, Helleman J, Boersma AW et al. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells. Oncogene 32(36), 4284-4293 (2013).
114. Ziliak D, Gamazon ER, Lacroix B, Im HK, Wen YJ, Huang RS. Genetic variation that predicts platinum sensitivity reveals the role of miR-193b∗ in chemotherapeutic susceptibility. Mol. Cancer Ther. 11(9), 2054-2061 (2012).
115. Cheng W, Liu T, Wan X, Gao Y, Wang H. MicroRNA-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells. FEBS J. 279(11), 2047-2059 (2012).
116. Chen R, Alvero AB, Silasi DA et al. Regulation of IKKbeta by miR-199a affects NF-kappaB activity in ovarian cancer cells. Oncogene 27(34), 4712-4723 (2008).
117. Wang ZX, Ting Z, Li Y, Chen G, Lu YP, Hao X. microRNA-199a is able to reverse cisplatin resistance in human ovarian cancer cells through the inhibition of mammalian target of rapamycin. Oncol. Lett. 6(3), 789-794 (2013).
118. Yang H, Kong W, He L et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 68(2), 425-433 (2008).
119. De Cecco L, Berardi M, Sommariva M et al. Increased sensitivity to chemotherapy induced by CpG-ODN treatment is mediated by microRNA modulation. PLoS ONE 8(3), e58849 (2013).
120. Ye G, Fu G, Cui S et al. MicroRNA 376c enhances ovarian cancer cell survival by targeting activin receptor-like kinase 7: implications for chemoresistance. J. Cell Sci. 124(Pt 3), 359-368 (2011).
121. Wang L, Mezencev R, Svajdler M, Benigno BB, Mcdonald JF. Ectopic over-expression of miR-429 induces mesenchymal-to-epithelial transition (MET) and increased drug sensitivity in metastasizing ovarian cancer cells. Gynecol. Oncol. 134(1), 96-103 (2014).
122. Wu H, Xiao Z, Zhang H, Wang K, Liu W, Hao Q. MiR-489 modulates cisplatin resistance in human ovarian cancer cells by targeting Akt3. Anti-Cancer Drugs 25(7), 799-809 (2014).
123. Pang YX, Mao HL, Shen L, Zhao Z, Liu RH, Liu PS. MiR-519d represses ovarian cancer cell proliferation and enhances cisplatin-mediated cytotoxicity in vitro by targeting XIAP. Oncotargets Ther. 7, 587-597 (2014).